Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Abbott Laboratories current ratio improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023. |
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Abbott Laboratories quick ratio improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023 not reaching Q2 2023 level. |
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Abbott Laboratories cash ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Current Ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Current assets | 22,670) | 22,664) | 23,505) | 24,377) | 25,224) | 24,845) | 24,956) | 23,429) | 24,239) | 23,492) | 22,627) | 21,817) | 20,441) | 17,390) | 17,221) | 15,498) | 15,667) | 16,119) | 15,195) | 14,409) | ||||||
Current liabilities | 13,841) | 13,042) | 14,350) | 14,530) | 15,489) | 13,365) | 12,392) | 12,647) | 13,105) | 12,867) | 12,614) | 12,462) | 11,907) | 10,257) | 10,959) | 10,808) | 10,863) | 10,491) | 9,062) | 9,113) | ||||||
Liquidity Ratio | ||||||||||||||||||||||||||
Current ratio1 | 1.64 | 1.74 | 1.64 | 1.68 | 1.63 | 1.86 | 2.01 | 1.85 | 1.85 | 1.83 | 1.79 | 1.75 | 1.72 | 1.70 | 1.57 | 1.43 | 1.44 | 1.54 | 1.68 | 1.58 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Current Ratio, Competitors2 | ||||||||||||||||||||||||||
Cigna Group | 0.77 | 0.73 | 0.73 | 0.72 | 0.73 | 0.73 | 0.83 | 0.81 | 0.83 | 0.70 | 0.72 | 0.76 | 0.77 | 0.79 | 0.83 | 0.76 | 0.74 | 0.61 | 0.65 | 0.64 | ||||||
CVS Health Corp. | 0.86 | 0.86 | 0.86 | 0.92 | 0.94 | 0.94 | 0.91 | 0.88 | 0.88 | 0.94 | 0.95 | 0.93 | 0.91 | 0.95 | 0.98 | 0.99 | 0.94 | 0.92 | 0.95 | 0.95 | ||||||
Danaher Corp. | 1.68 | 2.26 | 2.08 | 1.89 | 1.89 | 1.78 | 1.75 | 1.68 | 1.43 | 1.48 | 2.26 | 2.05 | 1.86 | 2.08 | 2.20 | 1.32 | 5.19 | 3.43 | 2.32 | 2.18 | ||||||
Elevance Health Inc. | 1.44 | 1.41 | 1.44 | 1.43 | 1.40 | 1.35 | 1.36 | 1.36 | 1.47 | 1.48 | 1.49 | 1.57 | 1.55 | 1.59 | 1.64 | 1.53 | 1.65 | 1.70 | 1.64 | 1.61 | ||||||
Humana Inc. | 1.59 | 1.37 | 1.37 | 1.39 | 1.52 | 1.35 | 1.53 | 1.53 | 1.62 | 1.72 | 1.71 | 1.67 | 1.77 | 1.81 | 1.69 | 1.66 | 1.82 | 1.83 | 1.75 | 1.65 | ||||||
Intuitive Surgical Inc. | 4.76 | 5.31 | 5.22 | 5.26 | 4.40 | 5.10 | 5.36 | 5.22 | 5.08 | 5.58 | 5.99 | 6.71 | 6.86 | 7.04 | 6.38 | 4.96 | 4.53 | 4.64 | 5.04 | 5.44 | ||||||
Medtronic PLC | 2.39 | 1.76 | 1.76 | 1.58 | 1.86 | 2.61 | 2.91 | 2.89 | 2.65 | 2.10 | 2.16 | 1.87 | 2.13 | 2.75 | 2.77 | 2.67 | 2.59 | 2.36 | 2.56 | 2.46 | ||||||
Shockwave Medical Inc. | 11.76 | 14.43 | 5.69 | 4.16 | 7.25 | 7.29 | 5.32 | 6.07 | 5.54 | 6.36 | 6.66 | 6.96 | 9.63 | 12.21 | 14.90 | 10.53 | 9.03 | 6.76 | 9.13 | 10.37 | ||||||
UnitedHealth Group Inc. | 0.79 | 0.80 | 0.80 | 0.81 | 0.77 | 0.82 | 0.77 | 0.78 | 0.79 | 0.77 | 0.77 | 0.74 | 0.74 | 0.82 | 0.84 | 0.75 | 0.69 | 0.70 | 0.67 | 0.73 |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Current ratio = Current assets ÷ Current liabilities
= 22,670 ÷ 13,841 = 1.64
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Abbott Laboratories current ratio improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023. |
Quick Ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Cash and cash equivalents | 6,896) | 6,709) | 7,835) | 9,161) | 9,882) | 9,594) | 8,937) | 7,675) | 9,799) | 9,302) | 8,658) | 8,054) | 6,838) | 4,480) | 4,763) | 3,377) | 3,860) | 4,091) | 3,137) | 3,022) | ||||||
Short-term investments | 383) | 338) | 320) | 371) | 288) | 313) | 353) | 483) | 450) | 390) | 286) | 318) | 310) | 251) | 274) | 291) | 280) | 244) | 239) | 239) | ||||||
Trade receivables, less allowances | 6,565) | 6,499) | 6,172) | 6,020) | 6,218) | 6,408) | 7,199) | 7,179) | 6,487) | 6,405) | 6,113) | 6,096) | 6,414) | 5,649) | 5,140) | 5,292) | 5,425) | 5,450) | 5,548) | 5,345) | ||||||
Total quick assets | 13,844) | 13,546) | 14,327) | 15,552) | 16,388) | 16,315) | 16,489) | 15,337) | 16,736) | 16,097) | 15,057) | 14,468) | 13,562) | 10,380) | 10,177) | 8,960) | 9,565) | 9,785) | 8,924) | 8,606) | ||||||
Current liabilities | 13,841) | 13,042) | 14,350) | 14,530) | 15,489) | 13,365) | 12,392) | 12,647) | 13,105) | 12,867) | 12,614) | 12,462) | 11,907) | 10,257) | 10,959) | 10,808) | 10,863) | 10,491) | 9,062) | 9,113) | ||||||
Liquidity Ratio | ||||||||||||||||||||||||||
Quick ratio1 | 1.00 | 1.04 | 1.00 | 1.07 | 1.06 | 1.22 | 1.33 | 1.21 | 1.28 | 1.25 | 1.19 | 1.16 | 1.14 | 1.01 | 0.93 | 0.83 | 0.88 | 0.93 | 0.98 | 0.94 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Quick Ratio, Competitors2 | ||||||||||||||||||||||||||
Cigna Group | 0.54 | 0.61 | 0.61 | 0.59 | 0.58 | 0.61 | 0.52 | 0.48 | 0.48 | 0.58 | 0.59 | 0.64 | 0.66 | 0.46 | 0.50 | 0.42 | 0.41 | 0.51 | 0.53 | 0.53 | ||||||
CVS Health Corp. | 0.59 | 0.60 | 0.59 | 0.61 | 0.62 | 0.64 | 0.62 | 0.54 | 0.55 | 0.59 | 0.58 | 0.54 | 0.53 | 0.58 | 0.63 | 0.60 | 0.52 | 0.52 | 0.54 | 0.55 | ||||||
Danaher Corp. | 1.18 | 1.76 | 1.52 | 1.34 | 1.30 | 1.19 | 1.13 | 1.08 | 0.89 | 0.93 | 1.67 | 1.51 | 1.36 | 1.52 | 1.59 | 0.92 | 4.68 | 2.99 | 1.78 | 1.58 | ||||||
Elevance Health Inc. | 1.30 | 1.29 | 1.32 | 1.31 | 1.27 | 1.21 | 1.22 | 1.23 | 1.33 | 1.33 | 1.35 | 1.43 | 1.42 | 1.45 | 1.49 | 1.37 | 1.52 | 1.58 | 1.51 | 1.49 | ||||||
Humana Inc. | 1.24 | 1.15 | 1.16 | 1.18 | 1.20 | 1.13 | 1.21 | 1.21 | 1.20 | 1.32 | 1.28 | 1.26 | 1.37 | 1.47 | 1.35 | 1.29 | 1.47 | 1.51 | 1.36 | 1.32 | ||||||
Intuitive Surgical Inc. | 3.83 | 4.44 | 4.36 | 4.30 | 3.56 | 4.19 | 4.49 | 4.40 | 4.34 | 4.66 | 5.12 | 5.76 | 5.96 | 5.93 | 5.40 | 4.00 | 3.75 | 3.80 | 4.15 | 4.53 | ||||||
Medtronic PLC | 1.54 | 1.18 | 1.18 | 1.01 | 1.30 | 1.87 | 2.07 | 2.06 | 1.91 | 1.58 | 1.63 | 1.37 | 1.50 | 2.05 | 2.02 | 1.95 | 1.90 | 1.69 | 1.88 | 1.83 | ||||||
Shockwave Medical Inc. | 10.61 | 12.99 | 4.43 | 3.53 | 5.93 | 5.81 | 4.30 | 4.88 | 4.62 | 5.29 | 5.55 | 5.88 | 8.37 | 10.70 | 13.40 | 9.50 | 8.44 | 6.17 | 8.47 | 9.72 | ||||||
UnitedHealth Group Inc. | 0.73 | 0.75 | 0.74 | 0.75 | 0.70 | 0.77 | 0.71 | 0.72 | 0.72 | 0.71 | 0.71 | 0.68 | 0.68 | 0.75 | 0.76 | 0.66 | 0.63 | 0.64 | 0.62 | 0.66 |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 13,844 ÷ 13,841 = 1.00
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Abbott Laboratories quick ratio improved from Q2 2023 to Q3 2023 but then slightly deteriorated from Q3 2023 to Q4 2023 not reaching Q2 2023 level. |
Cash Ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Cash and cash equivalents | 6,896) | 6,709) | 7,835) | 9,161) | 9,882) | 9,594) | 8,937) | 7,675) | 9,799) | 9,302) | 8,658) | 8,054) | 6,838) | 4,480) | 4,763) | 3,377) | 3,860) | 4,091) | 3,137) | 3,022) | ||||||
Short-term investments | 383) | 338) | 320) | 371) | 288) | 313) | 353) | 483) | 450) | 390) | 286) | 318) | 310) | 251) | 274) | 291) | 280) | 244) | 239) | 239) | ||||||
Total cash assets | 7,279) | 7,047) | 8,155) | 9,532) | 10,170) | 9,907) | 9,290) | 8,158) | 10,249) | 9,692) | 8,944) | 8,372) | 7,148) | 4,731) | 5,037) | 3,668) | 4,140) | 4,335) | 3,376) | 3,261) | ||||||
Current liabilities | 13,841) | 13,042) | 14,350) | 14,530) | 15,489) | 13,365) | 12,392) | 12,647) | 13,105) | 12,867) | 12,614) | 12,462) | 11,907) | 10,257) | 10,959) | 10,808) | 10,863) | 10,491) | 9,062) | 9,113) | ||||||
Liquidity Ratio | ||||||||||||||||||||||||||
Cash ratio1 | 0.53 | 0.54 | 0.57 | 0.66 | 0.66 | 0.74 | 0.75 | 0.65 | 0.78 | 0.75 | 0.71 | 0.67 | 0.60 | 0.46 | 0.46 | 0.34 | 0.38 | 0.41 | 0.37 | 0.36 | ||||||
Benchmarks | ||||||||||||||||||||||||||
Cash Ratio, Competitors2 | ||||||||||||||||||||||||||
Cigna Group | 0.18 | 0.20 | 0.22 | 0.20 | 0.17 | 0.19 | 0.11 | 0.12 | 0.14 | 0.13 | 0.15 | 0.24 | 0.32 | 0.15 | 0.20 | 0.13 | 0.14 | 0.17 | 0.17 | 0.20 | ||||||
CVS Health Corp. | 0.14 | 0.20 | 0.21 | 0.24 | 0.23 | 0.28 | 0.22 | 0.16 | 0.18 | 0.20 | 0.17 | 0.15 | 0.18 | 0.19 | 0.27 | 0.21 | 0.15 | 0.14 | 0.17 | 0.16 | ||||||
Danaher Corp. | 0.71 | 1.31 | 1.02 | 0.85 | 0.71 | 0.64 | 0.53 | 0.49 | 0.32 | 0.35 | 1.07 | 0.93 | 0.82 | 0.94 | 0.99 | 0.52 | 4.04 | 2.40 | 1.08 | 0.84 | ||||||
Elevance Health Inc. | 0.87 | 0.90 | 0.92 | 0.91 | 0.86 | 0.87 | 0.86 | 0.86 | 0.95 | 0.97 | 0.97 | 1.08 | 1.04 | 1.04 | 1.10 | 0.95 | 1.08 | 1.14 | 1.07 | 1.04 | ||||||
Humana Inc. | 1.13 | 1.09 | 1.11 | 1.06 | 1.10 | 1.07 | 1.02 | 1.02 | 1.08 | 1.20 | 1.12 | 1.12 | 1.29 | 1.39 | 1.22 | 1.16 | 1.37 | 1.44 | 1.28 | 1.15 | ||||||
Intuitive Surgical Inc. | 3.15 | 3.86 | 3.77 | 3.59 | 2.90 | 3.50 | 3.78 | 3.58 | 3.66 | 3.98 | 4.42 | 5.04 | 5.30 | 5.27 | 4.85 | 3.44 | 3.13 | 3.11 | 3.37 | 3.79 | ||||||
Medtronic PLC | 0.88 | 0.77 | 0.79 | 0.63 | 0.85 | 1.26 | 1.37 | 1.36 | 1.27 | 1.17 | 1.18 | 0.99 | 1.06 | 1.33 | 1.27 | 1.25 | 1.16 | 1.03 | 1.20 | 1.21 | ||||||
Shockwave Medical Inc. | 9.51 | 11.73 | 3.22 | 2.94 | 4.80 | 4.62 | 3.40 | 3.94 | 3.89 | 4.54 | 4.85 | 5.30 | 7.91 | 10.19 | 13.04 | 9.08 | 8.14 | 5.88 | 8.13 | 9.45 | ||||||
UnitedHealth Group Inc. | 0.34 | 0.42 | 0.44 | 0.43 | 0.36 | 0.46 | 0.36 | 0.37 | 0.36 | 0.35 | 0.35 | 0.33 | 0.33 | 0.37 | 0.42 | 0.35 | 0.28 | 0.30 | 0.32 | 0.32 |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 7,279 ÷ 13,841 = 0.53
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Abbott Laboratories cash ratio deteriorated from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |